Understanding the DecisionDx-Melanoma Genetic Test: A Closer Look at Your Skin Cancer

A melanoma diagnosis brings a flood of questions. How serious is it? Has it spread? What happens next? For decades, dermatologists and oncologists have answered those questions using traditional staging, measuring the tumor's depth, looking for ulceration, and sometimes performing a sentinel lymph node biopsy. Those tools are still essential. But in recent years, a newer kind of test has joined the picture: a genetic test called DecisionDx-Melanoma that looks at the tumor itself to help predict how it is likely to behave.

If your dermatologist or oncologist has mentioned this test, or if you've come across it while researching your diagnosis, here is a plain-language guide to what it is, how it works, and what its results mean.

What is DecisionDx-Melanoma?

DecisionDx-Melanoma is a gene expression profile (GEP) test developed by Castle Biosciences. It analyzes the activity of 31 genes inside a sample of your melanoma tumor, the same tissue that was already removed during your biopsy or excision. No new procedure is needed; the lab works from the existing specimen.

The goal of the test is to estimate the risk that a cutaneous (skin) melanoma will spread, or metastasize, within the next five years. That information is added to, not used in place of, the traditional staging your care team is already doing.

How does it work?

Melanoma cells have a kind of molecular fingerprint. Some genes inside the tumor are turned up, others are turned down, and the overall pattern can hint at whether the cancer is biologically "quiet" or more aggressive. The DecisionDx-Melanoma test measures the expression levels of 31 specific genes and feeds them into an algorithm that places each tumor into one of four risk classes:

• Class 1A - Lowest risk of metastasis

• Class 1B - Low to intermediate risk

• Class 2A - Intermediate to high risk

• Class 2B - Highest risk

Importantly, the test does not tell you whether you will or will not have a recurrence. It estimates probability. A Class 2B result does not mean spread is certain, and a Class 1A result is not a guarantee that nothing will ever come back. It is one more piece of information that helps your care team build the right plan for you.

Who is the DecisionDx-Melanoma Genetic Test for?

The test is designed for people who have been diagnosed with invasive cutaneous melanoma. It is most often considered for patients with early-stage disease (roughly Stage I and Stage II), where traditional staging leaves the most uncertainty. In those cases, two tumors that look very similar under the microscope can sometimes behave very differently, and the gene expression profile can help separate them.

Your dermatologist or oncologist will decide whether the test is appropriate based on your specific tumor characteristics, your overall health, and the management decisions in front of you.

How can the results change my care?

The results are used as a conversation starter, not a verdict. Depending on your risk class, your team may discuss:

• Surveillance intensity. Patients with higher-risk results may benefit from more frequent skin exams, more regular imaging, or closer follow-up with their oncologist. Lower-risk results may support a less intensive schedule.

• Sentinel lymph node biopsy. For some thin melanomas where the decision is genuinely on the fence, the test can add useful information to the conversation.

• Referral to medical oncology. Higher-risk results sometimes prompt a discussion about whether to involve an oncologist earlier.

• Peace of mind. A lower-risk result, paired with reassuring traditional staging, can be genuinely reassuring during a stressful time.

It is worth saying clearly: the test does not change the melanoma itself. It changes how clearly we can see it.

What about the evidence?

DecisionDx-Melanoma has been studied in tens of thousands of patients across multiple peer-reviewed publications. The research suggests that, when combined with traditional staging, the test can refine prognosis, particularly for Stage I and Stage II patients, and that the risk classes correlate with actual rates of recurrence and survival.

Like any tool in medicine, it has limitations. It is not perfect. It does not replace staging, pathology, or clinical judgment. And it is one of several gene expression tests on the market, each with its own data and indications. Major guideline bodies have weighed in differently over the years on exactly where these tests fit, which is one reason the conversation with your care team matters so much.

Practical questions patients often ask

Does it hurt? Do I need another procedure? No. The lab uses tissue that was already removed during your biopsy or excision.

How long do results take? Typically about a week to two weeks after the lab receives the sample.

Will insurance cover it? Coverage varies by plan and by clinical situation. Castle Biosciences and your dermatology office can usually help check benefits in advance.

Should everyone with melanoma get this test? No. It is most useful in specific clinical scenarios, and your dermatologist will help decide whether it is right for you.

The bottom line

A melanoma diagnosis is hard, and uncertainty is one of the hardest parts of it. DecisionDx-Melanoma will not remove that uncertainty entirely, but it can sharpen the picture. By looking inside the tumor itself, it gives your care team another data point to personalize your follow-up plan, more vigilance where it is needed, more reassurance where it is warranted.

If you have been recently diagnosed and are wondering whether this test is appropriate for you, the best next step is a conversation with your dermatologist. Bring your questions, bring your concerns, and remember that you are not making these decisions alone.

Call us at (520) 382 - 3330 to talk to our team about this test or visit DecisionDx-Melanoma: The Leader in Genetic Testing for Melanoma for more information about Castle and their team.